106 related articles for article (PubMed ID: 10332533)
21. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
[TBL] [Abstract][Full Text] [Related]
22. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.
Hirsch A; Vander Els N; Straus DJ; Gomez EG; Leung D; Portlock CS; Yahalom J
J Clin Oncol; 1996 Apr; 14(4):1297-305. PubMed ID: 8648387
[TBL] [Abstract][Full Text] [Related]
23. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study.
Rueda A; Alba E; Ribelles N; Sevilla I; Ruiz I; Miramón J
J Clin Oncol; 1997 Mar; 15(3):1118-22. PubMed ID: 9060553
[TBL] [Abstract][Full Text] [Related]
24. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H
J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434
[TBL] [Abstract][Full Text] [Related]
25. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
Canellos GP
Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
[No Abstract] [Full Text] [Related]
26. Should MOPP-ABVD alone be standard for childhood Hodgkin's?
Constine LS
J Clin Oncol; 1998 Mar; 16(3):1235. PubMed ID: 9508214
[No Abstract] [Full Text] [Related]
27. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group.
Fryer CJ; Hutchinson RJ; Krailo M; Collins RD; Constine LS; Hays DM; Heller RM; Davis PC; Nachman J; O'Brien RT
J Clin Oncol; 1990 Dec; 8(12):1971-80. PubMed ID: 1700080
[TBL] [Abstract][Full Text] [Related]
28. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
29. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
[TBL] [Abstract][Full Text] [Related]
30. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90.
Landman-Parker J; Pacquement H; Leblanc T; Habrand JL; Terrier-Lacombe MJ; Bertrand Y; Perel Y; Robert A; Coze C; Thuret I; Donadieu J; Schaison G; Leverger G; Lemerle J; Oberlin O
J Clin Oncol; 2000 Apr; 18(7):1500-7. PubMed ID: 10735898
[TBL] [Abstract][Full Text] [Related]
31. Hairy cell leukemia responsive to chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
Patten E; Gill DP; Weiss GB
Cancer Treat Rep; 1983 Dec; 67(12):1147-8. PubMed ID: 6197166
[No Abstract] [Full Text] [Related]
32. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of Hodgkin's disease with ABVD].
Montserrat E; Carreras E; Rozman C; Olivé T; Bladé J; Cervantes F; Feliu E; Gardella S; Grañena A; Marín P
Med Clin (Barc); 1984 Dec; 83(18):739-41. PubMed ID: 6084157
[No Abstract] [Full Text] [Related]
34. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
Lipton JH; Gospodarowicz M; Reingold S
Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133
[TBL] [Abstract][Full Text] [Related]
36. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
37. [Early results of the treatment of Hodgkin's disease with alternating use in the CVPP and ABVD protocol].
Gabryś K; Kotlarek-Haus S; Sciborski R
Pol Tyg Lek; 1986 Feb; 41(7):195-8. PubMed ID: 2423994
[No Abstract] [Full Text] [Related]
38. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
39. MOPP, ABVD, or both to treat Hodgkin's disease.
Aisenberg AC
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
[No Abstract] [Full Text] [Related]
40. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
von Tresckow B; Plütschow A; Fuchs M; Klimm B; Markova J; Lohri A; Kral Z; Greil R; Topp MS; Meissner J; Zijlstra JM; Soekler M; Stein H; Eich HT; Mueller RP; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2012 Mar; 30(9):907-13. PubMed ID: 22271480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
